Investigation of in vitro activity of colistin and tygecyclin against Stenotrophomonas maltophilia isolates


Creative Commons License

Tanriverdi Çayci Y., Bıyık İ., Yilmaz G., BİLGİN K., Birinci A.

Journal of Experimental and Clinical Medicine (Turkey), cilt.38, sa.4, ss.529-532, 2021 (Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 4
  • Basım Tarihi: 2021
  • Doi Numarası: 10.52142/omujecm.38.4.24
  • Dergi Adı: Journal of Experimental and Clinical Medicine (Turkey)
  • Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, EMBASE
  • Sayfa Sayıları: ss.529-532
  • Anahtar Kelimeler: Colistin, MIC, S. maltophilia, Tygecyclin
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Stenotrophomonas maltophilia has emerged as an important opportunistic pathogen, causing infections whose management is often problematic due to its inherent resistance to many antibiotics. In this study, we aimed to investigate the antimicrobial susceptibility of colistin and tygecyclin as an alternative treatment options for S. maltophilia infections. A total of 122 S. maltophilia isolates were tested. Minimum inhibitory concentration (MIC) values of colistin and tygecycline were determined by broth microdilution method. Susceptibility of TMP/SMX and levofloxacin (LVX) were determined by disc diffusion method and MIC value of ceftazidime (CAZ) was determined by using E-test. Out of 122 S. maltophilia isolates, 5 (4%) of them were resistant to TMP-SXM. MIC range was 0.125- >512 μg/ml and MIC5064 μg/ml, MIC90512 μg/ml for colistin. MIC range for tygecyclin was detected as 0.5- >8, MIC502 μg/ml and MIC908 μg/ml. Tygecyclin resistance was detected as 66.4% according to the EUCAST guideline and 13.1% according to the USA-FDA breakpoints. And colistin resistance was determined as 86.9% according to both guidelines.